EUVIMEDEUVIMED entdecken
Crossref

Recent developments in the use of monoclonal antibodies targeting the type 2 cytokines for severe asthma treatment

Garry M Walsh

Advances in Pharmacology · 2023 · 31-54

DOI: 10.1016/bs.apha.2023.04.003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advances in Pharmacology, 2023. Verfasst von Garry M Walsh. Beteiligte Einrichtung: Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, United Kingdom. Electronic address: g.m.walsh@abdn.ac.uk. Hauptthemen laut MEDLINE: Anti-Asthmatic Agents, Asthma. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 105 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Asthmatic AgentsAsthmaHumansAntibodies, MonoclonalCytokinesQuality of LifeInterleukin-5

Stichwörter der Autor:innen

BenralizumabDupilumabIL-13IL-4IL-5MepolizumabReslizumabType 2 cytokines

Substanzen

Antibodies, MonoclonalCytokinesAnti-Asthmatic AgentsInterleukin-5

Autor:innen und Institutionen

  • Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, United Kingdom. Electronic address: g.m.walsh@abdn.ac.uk.

Zitieren

APA

Walsh, G. M. (2023). Recent developments in the use of monoclonal antibodies targeting the type 2 cytokines for severe asthma treatment. Advances in Pharmacology, 31-54. https://doi.org/10.1016/bs.apha.2023.04.003

Vancouver

Walsh GM. Recent developments in the use of monoclonal antibodies targeting the type 2 cytokines for severe asthma treatment. Advances in Pharmacology. 2023:31-54. doi:10.1016/bs.apha.2023.04.003

BibTeX
@article{Walsh2023,
  author = {Walsh, Garry M},
  title = {Recent developments in the use of monoclonal antibodies targeting the type 2 cytokines for severe asthma treatment},
  journal = {Advances in Pharmacology},
  year = {2023},
  pages = {31--54},
  doi = {10.1016/bs.apha.2023.04.003}
}
Kostenlos starten →